Show notes
In this episode of Medsider Radio, we had an insightful chat with Brian Fahey, CEO of Adona Medical, which is a Shifamed-portfolio company. The Adona Interatrial Shunt is a smart implant designed to enable individualized management of heart failure. Before Adona, Brian founded a critical care company, Niveus Medical. He also spent time at J&J Innovation, specializing in drug-device products for oncology, and contributed to the leadership team at Arrinex, a neuromodulation company in the ENT space. An alumnus of the Stanford Biodesign Innovation Program, Brian holds a Ph.D. from Duke University.In this interview, Brian talks about the importance of identifying and mitigating medtech’s three major risk factors, how to assess ideas strategically, and how to approach investors and potential M&A transactions. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Brian Fahey.